Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel
NASDAQ:INBX

Inhibrx Biosciences Q3 2026 Earnings Date & Estimates

Inhibrx Biosciences logo
$89.09 -1.41 (-1.56%)
As of 12:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Inhibrx Biosciences is estimated to report Q3 2026 earnings on Friday, November 13, 2026, after market closes. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Inhibrx Biosciences in Q3 2026

Inhibrx Biosciences is expected to post earnings of -$2.45 per share on revenue of $1.90 million. In the same quarter a year earlier Inhibrx Biosciences reported -$2.28 per share. Inhibrx Biosciences last reported on August 13, 2026, posting -$2.34 per share and missing the -$2.28 consensus estimate. Inhibrx Biosciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$2.45
Expected Revenue
$1.90 million
Prior-Year EPS
-$2.28

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.34 (Missed by -$0.06)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Inhibrx Biosciences Q3 2026 Earnings FAQ

Inhibrx Biosciences (NASDAQ:INBX) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Inhibrx Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Inhibrx Biosciences to post earnings of -$2.45 per share for Q3 2026.

The consensus revenue estimate for Inhibrx Biosciences is $1.90 million for Q3 2026.

Inhibrx Biosciences Earnings Headlines

Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?
October 14 at 12:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/inhibrx-biosciences-inbx-global-data-141445384.html
Inhibrx Announces Participation in Upcoming Scientific Conferences
October 13 at 4:00 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conferences-302907553.html
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
October 16 at 1:00 AM  |  Weiss Ratings (Ad)
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/inhibrx-biosciences-inbx-faces-pipeline-110851641.html
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
September 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/inhibrx-cancer-drug-nearly-doubled-170714117.html
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
September 15, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/09/15/inhibrx-founder-and-ceo-mark-lappe-buys-25-000-shares-for-usd2-6-million-what-does-his-confidence-tell-investors/
See More Inhibrx Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx Biosciences and other key companies, straight to your email.

About Inhibrx Biosciences

Inhibrx Biosciences (NASDAQ:INBX) is a biotechnology company focused on discovering and developing engineered biologic medicines for serious diseases with limited treatment options. The company’s platform has been used to create multifunctional proteins and antibody-based therapies designed to address targets that may be difficult to treat with conventional drugs.

Its leading program was INBRX-101, an engineered recombinant human alpha-1 antitrypsin therapy developed for patients with alpha-1 antitrypsin deficiency-associated lung disease. Inhibrx also advanced additional investigational therapies, including INBRX-109, an antibody-based treatment candidate studied in oncology. These products have been evaluated through clinical development programs rather than commercialized as approved medicines by the company.

Inhibrx was founded in 2010 and was based in La Jolla, California. In 2024, Sanofi completed its acquisition of Inhibrx, gaining rights to the company’s principal programs, including INBRX-101. The company’s development activities and clinical programs have been directed primarily toward patients in the United States and other international markets through global research and clinical-trial efforts.

View Inhibrx Biosciences Profile
Earnings Tools